The cardiovascular risk on TRT is almost entirely a monitoring problem disguised as a drug problem. The largest trial we have found no increase in major cardiac events even in high-risk men, but that result only holds if the right markers are being tracked on the right schedule, and most clinics aren’t doing that. The danger, when there is one, usually isn’t the testosterone. It’s the bloodwork nobody ordered.
So this article skips the “is TRT bad for your heart” debate, which has an answer most articles won’t commit to, and goes straight to the part you can act on: the specific numbers, what they mean, and when each one demands a change.
What TRT Actually Does to Your Cardiovascular Markers
Forget “may affect.” Here are the actual, measurable effects, with direction and magnitude where the evidence is consistent.
- Hematocrit: the proportion of your blood made up of red blood cells, rises in most men on TRT. The increase is more pronounced with injections than gels, and it averages roughly 3–5 percentage points in the first six months. This is the single most clinically important cardiovascular marker to monitor, and it’s the one most commonly under-monitored.
- Blood pressure: rises modestly in some men, typically 5–10 mmHg systolic (the top number, the pressure when your heart beats) in those affected. The key detail most articles miss: this is usually driven by fluid retention from elevated estradiol (the form of estrogen testosterone converts into), not by testosterone directly. That distinction matters, because it means the fix is often estradiol management, not blood pressure medication.
- HDL cholesterol: the “good” cholesterol that helps clear fat from arteries, is mildly suppressed, more so with injectable and oral testosterone than topical. The average decrease is around 5–10%. Whether a drop of that size is clinically meaningful is genuinely debated, not settled in either direction.
- LDL cholesterol: the “bad” cholesterol, is variable. Some men see a modest increase, some see no change. The effect is far less consistent than the HDL effect.
Of these four, hematocrit is the one that requires the most specific monitoring protocol and the most attention. It’s worth its own section.
Hematocrit: The Number That Matters Most
Here’s the mechanism, because understanding it tells you why the monitoring schedule is what it is.
Testosterone stimulates red blood cell production through two pathways: it raises erythropoietin (EPO, the hormone that signals your bone marrow to make red blood cells) and it suppresses hepcidin (the protein that regulates how much iron is available for that production). The result is more red blood cells, which raises hematocrit. Higher hematocrit means more viscous, thicker, blood, and thicker blood raises clot risk. At the extreme, this becomes erythrocytosis, sometimes called polycythemia (a clinically significant overproduction of red blood cells). This isn’t theoretical; it’s a real, manageable concern that’s the main reason hematocrit monitoring is non-negotiable on TRT.
What the numbers actually mean:
| Hematocrit | What it means | What happens |
| Below 50% | Normal on TRT | No action required |
| 50–52% | Elevated but common in year one | Retest in 6–8 weeks; flag it with your clinic |
| 52–54% | Action zone | Protocol adjustment warranted, discuss increasing injection frequency or reducing dose |
| Above 54% (confirmed on retest) | Intervention threshold | Therapeutic phlebotomy indicated; don’t wait for the next scheduled appointment |
The 54% figure isn’t arbitrary or clinic-specific. It’s the threshold where the Endocrine Society, the American Urological Association, and the European Association of Urology converge: above a confirmed 54%, testosterone should be held or the dose reduced, and therapeutic phlebotomy (clinically supervised blood removal, mechanically similar to donating blood) is an effective intervention (Endocrine Society Clinical Practice Guidelines).
Why injections raise hematocrit faster than gels: injectable testosterone produces supraphysiological peaks, levels briefly higher than your body could ever produce on its own, in the days after a dose. Those peaks stimulate more red blood cell production than the steady, lower-level delivery of a daily gel. The practical consequence: men on injections should retest hematocrit at 6 weeks after starting, not 3 months. Men on gels can wait until 3 months.
Blood donation as a first-line tool: donating blood every 8–12 weeks is both effective hematocrit management and genuinely useful to someone else. Many men on stable protocols who donate regularly hold their hematocrit in the 46–50% range without any dose changes at all. This is worth raising with your clinic before a dose reduction is discussed, because it solves the problem without sacrificing symptom control.
What the Research Actually Shows
The cardiovascular fear around TRT traces to a specific timeline, and seeing it laid out is more useful than reading it as prose:
| Year | Evidence | What it actually showed |
| 2013–2014 | Two observational studies | Conducted in populations including men with significant pre-existing cardiovascular disease, not typical TRT patients. Both later found to have serious methodological flaws. |
| 2014–2023 | Media amplification + FDA warning | Drove a ~50% decline in testosterone prescribing. Still shapes how the topic is discussed today. |
| 2023 | TRAVERSE trial (NEJM) | The largest RCT to date. Directly contradicted the earlier fear in the highest-risk population. |
Why TRAVERSE is the number that matters. It was a randomized controlled trial of 5,246 men with hypogonadism (clinically low testosterone) who also had pre-existing cardiovascular disease or high risk for it, the exact population the 2013–2014 studies raised alarms about.
Over an average follow-up of ~33 months, testosterone therapy was noninferior to placebo for major adverse cardiac events (the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke). In plain terms: in the highest-risk realistic population, properly dosed testosterone did not increase the rate of the events people fear most (Lincoff et al., NEJM 2023).
This is not the same as “zero signal.” TRAVERSE did find higher rates of two specific things in the testosterone group:
- Non-fatal arrhythmias, irregular heart rhythms, mainly atrial fibrillation (a rapid, irregular beat of the heart’s upper chambers)
- Venous thromboembolism, blood clots forming in veins
These are real findings worth knowing. But they sit alongside a clear primary result that contradicts the headline fear, and that primary result is largely missing from competitor articles still citing the decade-old observational data.
Where genuine uncertainty still remains is narrower than the internet implies: men with a recent cardiac event, men with severe untreated sleep apnea, and men with uncontrolled high blood pressure. For those specific groups the evidence is thinner and the calculation is individual, not generic.
Who Faces Elevated Risk
This isn’t a list of people who can’t have TRT. It’s a framework for who needs a more rigorous monitoring protocol and a more careful starting conversation.
- Recent cardiac event (within ~6 months): Not an appropriate window to start TRT. TRAVERSE specifically excluded these patients, so we don’t have good evidence for this group, and absence of evidence here means caution, not reassurance.
- Untreated sleep apnea: Sleep apnea independently raises cardiovascular risk and also drives its own hematocrit elevation through low overnight oxygen. TRT can worsen sleep apnea. The order matters: treat the sleep apnea first, or start TRT only with close monitoring if treatment isn’t immediately available.
- Uncontrolled hypertension: TRT’s modest blood pressure effect is minor in isolation but becomes clinically meaningful when baseline pressure is already elevated. Get the hypertension controlled first, then reassess, this is sequencing, not exclusion.
- Pre-existing erythrocytosis: If your hematocrit is already elevated before starting, any further increase is significant. TRT isn’t off the table, but it requires more aggressive monitoring and likely a lower starting dose.
Having one of these doesn’t end the conversation. It changes what the conversation has to include.
Your Monitoring Checklist
These aren’t optional extras. They’re the specific data points that determine whether your protocol is working safely.
| Test | What it monitors | When (year one) | When (stable) | Number that triggers action |
| CBC, hematocrit | Red blood cell count / blood thickness | 6 weeks after starting, then every 3 months | Every 6 months | Above 52% → discuss; confirmed above 54% → act |
| Blood pressure | Fluid retention / BP effect | Every clinic visit | Every clinic visit | Consistently above 140/90 → discuss |
| Lipid panel | HDL / LDL cholesterol | At 6 months | Annually | Significant HDL drop or LDL rise → discuss |
| Estradiol | Source of fluid retention | 6 weeks after starting | With every testosterone panel | Elevated → manage estradiol before reaching for BP medication |
The estradiol row is the one most commonly skipped, and it’s frequently the lever that fixes blood pressure changes without adding another medication.
What Your Clinic Should Be Doing, and What to Ask If They’re Not
Cardiovascular-specific standard of care that often gets missed:
- Hematocrit tested at 6 weeks after initiation, not 3 months, especially for men on injections, where it rises faster
- Estradiol tested at every panel, elevated estradiol is the most common and most treatable driver of fluid retention and blood pressure changes on TRT
- Blood pressure measured at every visit, not assumed from what you report
- 54% used as the hematocrit phlebotomy threshold, not 50% (overly conservative, costs you symptom control) and not 60% (unsafely permissive)
- TRAVERSE used to frame cardiovascular risk discussions, not the 2013–2014 observational studies
One blunt test: if your clinic’s cardiovascular monitoring is an annual testosterone level and a once-a-year blood pressure check, that is not adequate monitoring for a man on TRT. That’s worth raising directly, or treating as a reason for a second opinion.
The Bottom Line
Everything in this article reduces to one practical idea: on TRT, the heart risk that matters is the one your monitoring catches early, and the one that hurts people is the one nobody was looking for. The starting decision is reassuring for most healthy men. The monitoring decision is the one you actually have leverage over.
If you have hypertension, sleep apnea, or a family history of cardiovascular disease and you want a straight answer about your individual risk rather than a label-driven one, that’s worth settling before you start or continue. Action TRT sizes the monitoring protocol to your specific risk rather than a one-schedule-fits-all default, which, on this particular topic, is the difference that does the work.
